Chlordiazepoxide
FDA-approved product (capsule, extended release, oral), marketed as Librelease, Libritabs, A-Poxide and 4 more.
- Registered studies
- 8
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Alcohol dependence
- Anxiety
- Anxiety disorder
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Benzodiazepine derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae8.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
8registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Chlordiazepoxide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Stellate Ganglion Block Versus Oral Medication in Treatment of Palmar Hyperhidrosis
NCT06731101 · start 2025-01-15
Registered record
- Registry ID
- NCT06731101
- Conditions
- Palmar Hyperhidrosis
- Interventions
- Bupivacaine + Lidocaine +dexamethasone; Tryptizole + Librax
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2025-01-15
- Completion
- 2026-01-01
- Enrolment
- 46
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPalmar HyperhidrosisInterventionBupivacaine + Lidocaine +dexamethasone; Tryptizole + LibraxPhaseNot applicableRegistry statusCompletedMetabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms
NCT05563350 · start 2022-01-29
Registered record
- Registry ID
- NCT05563350
- Conditions
- Alcohol Withdrawal
- Interventions
- Blood samples
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2022-01-29
- Completion
- 2023-07-01
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlcohol WithdrawalInterventionBlood samplesPhaseNot recordedRegistry statusCompletedGabapentin for Alcohol Withdrawal Syndrome
NCT03012815 · start 2017-02-01
Registered record
- Registry ID
- NCT03012815
- Conditions
- Alcohol Withdrawal Syndrome
- Interventions
- Gabapentin; Benzodiazepines; Divalproex Sodium
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2017-02-01
- Completion
- 2021-03-01
- Enrolment
- 88
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlcohol Withdrawal SyndromeInterventionGabapentin; Benzodiazepines; Divalproex SodiumPhasePhase 4Registry statusCompletedTreatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants
NCT05438641 · start 2013-08
Registered record
- Registry ID
- NCT05438641
- Conditions
- Alcohol Withdrawal Syndrome
- Interventions
- BZDP-Sparing Protocol; BZDP-Based Protocol
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2013-08
- Completion
- 2017-08
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlcohol Withdrawal SyndromeInterventionBZDP-Sparing Protocol; BZDP-Based ProtocolPhaseNot recordedRegistry statusCompletedPioglitazone as an Adjunct for Moderate to Severe Depressive Disorder
NCT01109030 · start 2010-04
Registered record
- Registry ID
- NCT01109030
- Conditions
- Major Depressive Disorder
- Interventions
- Pioglitazone+Citalopram+Chlordiazepoxide; Placebo+ Citalopram+ Chlordiazepoxide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2010-04
- Completion
- 2011-10
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMajor Depressive DisorderInterventionPioglitazone+Citalopram+Chlordiazepoxide; Placebo+ Citalopram+ ChlordiazepoxidePhasePhase 2 / Phase 3Registry statusCompletedGabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
NCT01573052 · start 2004-03
Registered record
- Registry ID
- NCT01573052
- Conditions
- Alcohol Withdrawal
- Interventions
- Chlordiazepoxide; Gabapentin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-03
- Completion
- 2010-09
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlcohol WithdrawalInterventionChlordiazepoxide; GabapentinPhasePhase 4Registry statusCompletedOutpatient Treatment of Alcohol Withdrawal Syndrome
NCT00136617 · start 2003-08
Registered record
- Registry ID
- NCT00136617
- Conditions
- Alcoholism; Alcohol Withdrawal
- Interventions
- chlordiazepoxide
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-08
- Completion
- 2008-09
- Enrolment
- 165
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlcoholism; Alcohol WithdrawalInterventionchlordiazepoxidePhasePhase 3Registry statusCompletedA Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study
NCT00516854 · start 2002-06
Registered record
- Registry ID
- NCT00516854
- Conditions
- Chest Pain
- Interventions
- chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2002-06
- Completion
- 2008-12
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChest PainInterventionchlordiazepoxide 5 mg, clidinium 2.5 mg, twice dailyPhaseNot applicableRegistry statusUnknown